Vera Therapeutics announced that TRUTAKNA met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 trial for primary IgA nephropathy. In a 428-patient set, TRUTAKNA stabilized eGFR with a mean change of -0.1 mL/min/1.73m² versus -5.7 for placebo (p<0.0001) and reduced composite kidney disease progression by 76% (HR 0.24). The company plans to submit a supplemental BLA for full approval in Q4 2026, targeting potential approval in 2027. Vera Therapeutics is a commercial-stage biotechnology company developing treatments for autoimmune diseases.

Vera Therapeutics reported a net loss of $109.5 million for the second quarter ended June 30, 2026, compared to a $76.5 million loss in the prior year period. The company announced the commercial launch of TRUTAKNA, its first FDA-approved therapy for IgA nephropathy (IgAN), and aligned with regulators on an earlier final efficacy analysis from the ORIGIN 3 trial expected in Q3 2026 to support full approval. Vera also appointed Nancy Boman as Chief Regulatory Officer, succeeding William Turner who is transitioning to Strategic Advisor. The company held $499.2 million in cash and marketable securities at quarter-end. Vera Therapeutics operates in the biotechnology industry, focusing on developing therapies for autoimmune diseases.

Vera Therapeutics, Inc. announced a leadership transition in its regulatory department, with William Turner transitioning to Special Advisor for Regulatory Affairs effective August 3, 2026, and Nancy Bowman, M.D., Ph.D., succeeding him as Chief Regulatory Officer. Vera Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for immune-mediated diseases.

On July 7, 2026, the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA™ (atacicept-vymj). The therapy is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases.